Biotech startups that raised Series B in New York, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Evvy | New York | Series B | $40.0M | 2026-09-15 |
| Clarapath | New York | Series B | $36.0M | 2024-07-24 |
| Retia Medical | White Plains | Series B | $15.0M | 2022-07-18 |
| Massive Bio | New York | Series B | $17.0M | 2022-06-02 |
| ARMGO Pharma | Tarrytown | Series B | $35.0M | 2021-12-20 |
| Immunai | New York | Series B | $215.0M | 2021-10-27 |
| Pymetrics | New York | Series B | $40.0M | 2018-09-27 |
7 rows of the CSV in 5 of its 18 columns.
- The 32 biotech startups in New York, United States whose last round is Series B have raised $2.0B in total.
- 3 of them closed their most recent round in the last 12 months, $120.2M combined.
- The largest of those rounds is Paradigm's $78.0M Series B, dated December 2025.
- The most recent is Evvy's $40.0M Series B on 15 September 2026.
- Health care is the most common other sector, with 27 companies (84%).
- 16% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (48% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
4 of 32| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | New York | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
| Massive Bio | Massive Bio runs an AI oncology platform that matches patients with clinical trials and gives pharma companies access to them. | Artificial intelligence | New York | Series B | $17.0M | 2022-06-02 | $23.8M | 500 Global, 500 Emerging Europe, KFW DEG | 101 to 250 | 2015 |
| Immunai Unicorn | Immunai applies machine learning and software engineering to map and reprogram immunology. | Artificial intelligence | New York | Series B | $215.0M | 2021-10-27 | $295.0M | 8VC, TLV Partners, Alexandria Venture Investments +2 | 101 to 250 | 2018 |
| Pymetrics | Pymetrics develops neuroscience-based assessment technology that predicts candidate fit for staffing firms. | Artificial intelligence | New York | Series B | $40.0M | 2018-09-27 | $56.6M | MassChallenge, Khosla Ventures, Salesforce Ventures +2 | 101 to 250 | 2011 |
Table 1. Biotech startups that raised Series B in New York, United States: the 4 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 32.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | New York | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series B in New York, United States: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | G9 Ventures | Venture capital firm | New York, United States | 1 | 3% | 1 | Evvy |
| 2 | General Catalyst | Venture capital firm | San Francisco, United States | 1 | 3% | 1 | Evvy |
| 3 | BoxGroup | Venture capital firm | New York, United States | 1 | 3% | 1 | Evvy |
| 4 | Human Ventures | Angel group | New York, United States | 1 | 3% | 1 | Evvy |
| 5 | Left Lane Capital | Venture capital firm | Brooklyn, United States | 1 | 3% | 1 | Evvy |
| 6 | East Post Road Ventures | Venture capital firm | White Plains, United States | 1 | 3% | ||
| 7 | The CU Healthcare Innovation Fund | Venture capital firm | Aurora, United States | 1 | 3% | ||
| 8 | Northwell Ventures | Corporate venture arm | New Hyde Park, United States | 1 | 3% | ||
| 9 | Red Cedar Ventures | Venture capital firm | East Lansing, United States | 1 | 3% | ||
| 10 | Pritzker/Vlock Family Office | Family office | Chicago, United States | 1 | 3% | ||
| 11 | KFW DEG | Private equity firm | Cologne, Germany | 1 | 3% | ||
| 12 | 500 Global | Startup accelerator | Palo Alto, United States | 1 | 3% | ||
| 13 | 500 Emerging Europe | Venture capital firm | San Francisco, United States | 1 | 3% | ||
| 14 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 1 | 3% | ||
| 15 | Pontifax | Venture capital firm | Herzliya, Israel | 1 | 3% |
Table 3. Biotech startups that raised Series B in New York, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 27 | 84% | $1.8B |
| Software | 6 | 19% | $492.4M |
| Artificial intelligence | 4 | 12% | $434.4M |
| Hardware | 2 | 6% | $22.0M |
| Fintech | 2 | 6% | $350K |
| Energy | 1 | 3% | $350K |
| Commerce | 1 | 3% |
Table 4. Biotech startups that raised Series B in New York, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 32 | 100% | $36.0M |
Table 5. Biotech startups that raised Series B in New York, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| New York | 27 | 84% |
| Brooklyn | 1 | 3% |
| White Plains | 1 | 3% |
| Tarrytown | 1 | 3% |
| West Henrietta | 1 | 3% |
| Orangeburg | 1 | 3% |
Table 6. Biotech startups that raised Series B in New York, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 1 | 33% | $40.0M |
| January 2026 | 1 | 33% | $2.2M |
| December 2025 | 1 | 33% | $78.0M |
Table 7. Biotech startups that raised Series B in New York, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 2 | 6% | $42.2M |
| 2025 | 2 | 6% | $78.0M |
| 2024 | 3 | 9% | $296.0M |
| 2023 | 2 | 6% | $46.5M |
| 2022 | 3 | 9% | $32.0M |
| 2021 | 9 | 28% | $833.4M |
Table 8. Biotech startups that raised Series B in New York, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 5 | 16% |
| 2015 to 2019 | 12 | 38% |
| 2010 to 2014 | 10 | 31% |
| Before 2010 | 5 | 16% |
Table 9. Biotech startups that raised Series B in New York, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 7 | 23% |
| 11 to 50 | 15 | 48% |
| 51 to 100 | 4 | 13% |
| 101 to 250 | 4 | 13% |
| 1,001 to 5,000 | 1 | 3% |
Table 10. Biotech startups that raised Series B in New York, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in New York, United States. On 16 November 2026 that is 32 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 4 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 32 rows: 5 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in New York, United States whose last round is Series B are on the list?
- 32, in the file dated 16 November 2026. 3 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 32 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.